MYX has improved over the last year or two, the share price...

MYX has improved over the last year or two, the share price movement down over the last few months doesn't correlate to this reporting. So IMO as there's much greater potential of upside if over the next 3 years the generics improves, especially in USA market. Last year the risks seemed higher, for around the same price. This year less risk, ( but similar price now).

I really like this US exposure, and Corbet and co in management, and in balancing this if there is some reporting improvements, the big boys aren't all paying attention. Not yet anyway, and it's showing, they don't seem to have conviction.

So what's the downside? Yes maybe it will bumble along, maybe fall another 10% ( or sales don't eventuate, or R&D doesn't pay off), but MYX has been in far worse position and still held up its price ok. The recent refinancing in Dec reporting seems like business as usual, refinance in 2023 sparked some thought...
They don't seem to be burning cash, not lately anyway.

So in a sense I am ok even if it sat flat for a little while longer, looking ahead. There's still some damage / uncertainty because of Trumps comments a year or so ago, targeting generic prices. Well hoo har. Trump looks likely to not last another term, and I am backing that in 2-3 years, any reticence of being in generics will pass. Then watch the sentiment turn.